Senti Bio Secures $2.5M Equity Commitment from Celadon Affiliate Ahead of Merger
SNTI is trading near its 52-week low of $0.331 (3.7% above the low) on light trading volume (0.2× avg).
Summary
Senti Bio obtained a $2.5 million equity commitment from a Celadon affiliate to be funded at the merger closing, alongside confirmation that the $2.0 million NSG convertible note tranche closed.
Key Events · Financing and Capital Events · SNTI
-
$2.5M Equity Commitment from Celadon Affiliate
CPIF II-9 Limited committed to purchase $2.5 million of newly issued common stock at the Nasdaq Minimum Price, to be funded at or around the merger closing.
-
Nasdaq Compliance Condition
The commitment is conditioned on the company submitting a Nasdaq compliance plan demonstrating ability to meet the minimum stockholders' equity requirement, and retaining at least $600,000 in cash after closing.
-
NSG Convertible Note Tranche Closes
The previously announced $2.0 million senior secured convertible note issuance to NSG BioInnovation Fund closed on September 3, 2026, with the note form amended to add NSG as a party.
-
Registration Rights Agreement Required
The equity commitment requires execution of a registration rights agreement at or prior to closing, providing the Celadon affiliate with demand and piggyback registration rights.
Analysis · SNTI · Life Sciences
A $2.5 million equity commitment from CPIF II-9 Limited, a Celadon Partners affiliate, has been locked in by Senti Bio. The funding is set to occur at the Nasdaq Minimum Price at or around the merger closing. This fresh capital helps satisfy the Nasdaq minimum stockholders' equity requirement — a condition of the commitment itself — and arrives just two days after the company received two Nasdaq delisting notices. The commitment is conditioned on the merger closing, the company retaining at least $600,000 in cash, and submission of a Nasdaq compliance plan, so it is not yet guaranteed. The filing also confirms the previously announced $2.0 million NSG convertible note tranche closed on September 3, 2026.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 30% of the 1973 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.12%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SNTI was trading at $0.34 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.6M. The 52-week trading range was $0.33 to $2.88. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.